Cargando…

ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia

Detalles Bibliográficos
Autores principales:	van Outersterp, Inge, van der Velden, Vincent H.J., Hoogeveen, Patricia G., Vaitkevičienė, Goda E., Sonneveld, Edwin, van Haaften, Gijs, Kuiper, Roland P., zur Stadt, Udo, Escherich, Gabriele, Boer, Judith M., den Boer, Monique L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511034/ https://www.ncbi.nlm.nih.gov/pubmed/37736661 http://dx.doi.org/10.1097/HS9.0000000000000967

Ejemplares similares

PB1706: ABL-CLASS GENOMIC BREAKPOINT Q-PCR FOR RELIABLE MEASURABLE RESIDUAL DISEASE MONITORING IN ALL PATIENTS
por: van Outersterp, Inge, et al.
Publicado: (2023)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

Characterization of novel, recurrent genomic rearrangements as sensitive MRD targets in childhood B-cell precursor ALL
por: zur Stadt, Udo, et al.
Publicado: (2019)

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia
por: Boer, Judith M., et al.
Publicado: (2016)

Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a population-based study
por: Norvilas, Rimvydas, et al.
Publicado: (2021)

Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR)
por: Weber, Axel, et al.
Publicado: (2012)

Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion
por: Stukaite-Ruibiene, Egle, et al.
Publicado: (2022)

Characterization of a novel MEF2D-BCL9 fusion-positive acute lymphoblastic leukemia cell line
por: van Outersterp, Inge, et al.
Publicado: (2023)

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
por: Cazzaniga, Giovanni, et al.
Publicado: (2018)

Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia
por: van der Veer, A, et al.
Publicado: (2014)

IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia
por: Lopes, Bruno A., et al.
Publicado: (2019)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.
por: Escherich, Gabriele, et al.
Publicado: (2021)

Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome
por: Oliveira, Elen, et al.
Publicado: (2022)

VNTR polymorphism in the breakpoint region of ABL1 and susceptibility to bladder cancer
por: Kim, Min-Hye, et al.
Publicado: (2021)

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients
por: Scheijen, Blanca, et al.
Publicado: (2017)

Highly sensitive MRD tests for ALL based on the IKZF1 Δ3–6 microdeletion
por: Venn, N C, et al.
Publicado: (2012)

Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest
por: Nachmias, Boaz, et al.
Publicado: (2023)

The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia
por: Østergaard, Anna, et al.
Publicado: (2023)

Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study
por: van der Velden, Vincent H. J., et al.
Publicado: (2021)

Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia
por: Möker, Paula, et al.
Publicado: (2022)

Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario
por: Tierens, Anne, et al.
Publicado: (2021)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
por: van der Linde, Riana, et al.
Publicado: (2023)

Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study
por: Michels, Naomi, et al.
Publicado: (2021)

Changes in Nutritional Status during Induction Phase and Their Association with Fever and Minimal Residual Disease in Paediatric Acute Lymphoblastic Leukaemia
por: Gustaitė, Sigita, et al.
Publicado: (2023)

Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
por: Massimino, Michele, et al.
Publicado: (2021)

Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods
por: Kotrová, Michaela, et al.
Publicado: (2022)

Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab
por: Kantarjian, Hagop M., et al.
Publicado: (2023)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

Should new health technology be available only for patients able and willing to pay?
por: Calcoen, Piet, et al.
Publicado: (2017)

Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia
por: Wojtuszkiewicz, Anna, et al.
Publicado: (2015)

Integrating copy number data of 64 iAMP21 BCP-ALL patients narrows the common region of amplification to 1.57 Mb
por: Hormann, Femke M., et al.
Publicado: (2023)

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)

Patient specific real-time PCR in precision medicine – Validation of IG/TR based MRD assessment in lymphoid leukemia
por: Schilhabel, Anke, et al.
Publicado: (2023)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia
por: Lopes, Bruno Almeida, et al.
Publicado: (2016)

Unravelling the Sequential Interplay of Mutational Mechanisms during Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia
por: Antić, Željko, et al.
Publicado: (2021)

NP-MRD: the Natural Products Magnetic Resonance Database
por: Wishart, David S, et al.
Publicado: (2021)

Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia
por: Steeghs, Elisabeth M. P., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gmq4hd5vim8lk883ptp7sk8up4